TAA-T
Phase 1Biologic
TAA-T is one of 16 biologic programs targeting Hodgkin Lymphoma. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
10 competitors in Hodgkin Lymphoma
#DrugCompanyPhaseTrials
1DTIC-Dome
BayerPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Adcetris
PfizerPhase 3
Velban
Eli LillyPhase 3
Adriamycin
PfizerPhase 3
Adriamycin
PfizerPhase 3
Keytruda
Merck & Co.Phase 2
Beyfortus
BeiGenePhase 2
TAA-T
CCatherine Bollard
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TAA-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- CCatherine Bollard